pharma · Opioid Use Disorder · Opioid Dependence
Indivior Pty
Indivior Pty Ltd
Indivior Pty clinical programs — 12 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- ., Richmond, VA, US
- Employees
- 967
- Programs
- 39
- Drugs
- 19
- Patents
- 34
Indivior Pty projects
12 ClinicalTrials.gov programs sponsored by Indivior Pty.
Indivior Pty has 12 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Arbaclofen Placarbil
Indivior Pty Ltd
Alcohol Use Disorder
1 trial -
Buprenorphine
Indivior Pty Ltd
Opioid Use Disorder
1 trial -
Buprenorphine hydrochloride marketed sublingual tablet (Subutex)
Indivior Pty Ltd
Opioid Dependency
1 trial -
Buprenorphine soluble film
Indivior Pty Ltd
Opioid-related Disorders
1 trial -
Buprenorphine/naloxone Film Strip
Indivior Pty Ltd
Opioid-Related Disorders
1 trial -
INDV-2000
Indivior Pty Ltd
Opioid Use Disorder
1 trial -
INDV-6001
Indivior Pty Ltd
Moderate to Severe Opioid Use Disorder
1 trial -
RBP-6000
Indivior Pty Ltd
Opioid Related Disorder
1 trial -
RBP-6300
Indivior Pty Ltd
Opioid Related Disorder
1 trial -
RBP-8000 100 mg
Indivior Pty Ltd
Opioid Dependence
1 trial -
Risperidone
Indivior Pty Ltd
Schizophrenia
1 trial -
XP19986 CR
Indivior Pty Ltd
GERD
1 trial
Frequently asked questions
How many clinical projects does Indivior Pty have?
12 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.